In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles

Sofia Perea, Gloria Gonzalez, Annette W. Fothergill, Deanna A. Sutton, Michael G. Rinaldi

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

A checkerboard microdilution method, performed according to the recommendations of the National Committee for Clinical Laboratory Standards, was used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles isolated from the oral cavities of human immunodeficiency virus patients. Synergy, defined as a fractional inhibitory concentration index of ≤0.5, was observed in 17% of TRB-FLU interactions, 21% of TRB-ITRA interactions, 33% of TRB-VRC interactions, and 12% of TRB-PSZ interactions. Where synergy was not achieved, there was still a decrease in the MIC of one or both drugs when used in combination. Antagonism was not observed in any drug combination. Clinical studies are warranted to elucidate the potential utility of these combination therapies.

Original languageEnglish (US)
Pages (from-to)1831-1833
Number of pages3
JournalJournal of Clinical Microbiology
Volume40
Issue number5
DOIs
StatePublished - 2002

Fingerprint

terbinafine
Candida glabrata
Azoles
Itraconazole
Fluconazole
Drug Combinations
Mouth
In Vitro Techniques
posaconazole
Voriconazole
HIV

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. / Perea, Sofia; Gonzalez, Gloria; Fothergill, Annette W.; Sutton, Deanna A.; Rinaldi, Michael G.

In: Journal of Clinical Microbiology, Vol. 40, No. 5, 2002, p. 1831-1833.

Research output: Contribution to journalArticle

@article{cd393da542a64b8f92113e0ecb43b1c8,
title = "In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles",
abstract = "A checkerboard microdilution method, performed according to the recommendations of the National Committee for Clinical Laboratory Standards, was used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles isolated from the oral cavities of human immunodeficiency virus patients. Synergy, defined as a fractional inhibitory concentration index of ≤0.5, was observed in 17{\%} of TRB-FLU interactions, 21{\%} of TRB-ITRA interactions, 33{\%} of TRB-VRC interactions, and 12{\%} of TRB-PSZ interactions. Where synergy was not achieved, there was still a decrease in the MIC of one or both drugs when used in combination. Antagonism was not observed in any drug combination. Clinical studies are warranted to elucidate the potential utility of these combination therapies.",
author = "Sofia Perea and Gloria Gonzalez and Fothergill, {Annette W.} and Sutton, {Deanna A.} and Rinaldi, {Michael G.}",
year = "2002",
doi = "10.1128/JCM.40.5.1831-1833.2002",
language = "English (US)",
volume = "40",
pages = "1831--1833",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles

AU - Perea, Sofia

AU - Gonzalez, Gloria

AU - Fothergill, Annette W.

AU - Sutton, Deanna A.

AU - Rinaldi, Michael G.

PY - 2002

Y1 - 2002

N2 - A checkerboard microdilution method, performed according to the recommendations of the National Committee for Clinical Laboratory Standards, was used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles isolated from the oral cavities of human immunodeficiency virus patients. Synergy, defined as a fractional inhibitory concentration index of ≤0.5, was observed in 17% of TRB-FLU interactions, 21% of TRB-ITRA interactions, 33% of TRB-VRC interactions, and 12% of TRB-PSZ interactions. Where synergy was not achieved, there was still a decrease in the MIC of one or both drugs when used in combination. Antagonism was not observed in any drug combination. Clinical studies are warranted to elucidate the potential utility of these combination therapies.

AB - A checkerboard microdilution method, performed according to the recommendations of the National Committee for Clinical Laboratory Standards, was used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles isolated from the oral cavities of human immunodeficiency virus patients. Synergy, defined as a fractional inhibitory concentration index of ≤0.5, was observed in 17% of TRB-FLU interactions, 21% of TRB-ITRA interactions, 33% of TRB-VRC interactions, and 12% of TRB-PSZ interactions. Where synergy was not achieved, there was still a decrease in the MIC of one or both drugs when used in combination. Antagonism was not observed in any drug combination. Clinical studies are warranted to elucidate the potential utility of these combination therapies.

UR - http://www.scopus.com/inward/record.url?scp=0036246146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036246146&partnerID=8YFLogxK

U2 - 10.1128/JCM.40.5.1831-1833.2002

DO - 10.1128/JCM.40.5.1831-1833.2002

M3 - Article

C2 - 11980970

AN - SCOPUS:0036246146

VL - 40

SP - 1831

EP - 1833

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 5

ER -